Increased inflammatory markers in children with familial hypercholesterolaemia

European Journal of Clinical Investigation
T UelandAnne G Semb

Abstract

While data are abundant on increased levels of inflammatory markers in adult patients with hypercholesterolaemia, such data in children are limited. Therefore, we sought to investigate the degree and character of inflammation in children with heterozygous familial hypercholesterolaemia (FH) by measuring levels of neopterin, high-sensitivity C-reactive protein (hsCRP), and soluble CD40 ligand (sCD40L). In the present study, we compared the concentration of inflammatory markers in children suffering from heterozygous FH (n = 207) with those in unaffected siblings (n = 84). Furthermore, we investigated the effect of 2-year treatment with pravastatin (20-40 mg qd) or placebo on plasma levels of those markers. Our main finding was that serum levels of neopterin and hsCRP were significantly higher in FH children compared with healthy siblings, whereas sCD40L was not. Body mass index and high-density lipoprotein cholesterol levels were significant independent predictors of hsCRP and neopterin. Furthermore, pravastatin therapy decreased neopterin, but not hsCRP and sCD40L, in the FH children, but these changes were not different from the placebo group. These findings indicate low-grade monocyte/macrophage hyperactivity in the early sta...Continue Reading

References

Apr 3, 1997·The New England Journal of Medicine·P M RidkerC H Hennekens
Aug 1, 1997·The American Journal of Clinical Nutrition·N S Scrimshaw, J P SanGiovanni
Sep 1, 1997·Journal of the American College of Cardiology·M SchumacherW Klein
Dec 5, 1998·The New England Journal of Medicine·UNKNOWN Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
Jan 14, 1999·The New England Journal of Medicine·R Ross
Dec 2, 2000·Nature Medicine·B KwakF Mach
Nov 17, 2001·European Journal of Internal Medicine·P L van HaelstJ W Tervaert
Jan 25, 2002·Annals of the New York Academy of Sciences·L Robbie, P Libby
Mar 6, 2002·Circulation·Peter LibbyAttilio Maseri
Mar 13, 2002·Circulation·Johann W AuerBernd Eber
May 11, 2002·Current Drug Metabolism·C MurrD Fuchs
Mar 21, 2003·The New England Journal of Medicine·Christopher HeeschenUNKNOWN CAPTURE Study Investigators
Oct 29, 2003·Clinical Chemistry and Laboratory Medicine : CCLM·Roland B WalterWalter H Reinhart
Mar 31, 2004·The American Journal of Medicine·Peter Libby, Paul M Ridker
Jun 15, 2004·Journal of the American College of Cardiology·Pal AukrustNils Olav Solum
Jul 10, 2004·Current Opinion in Lipidology·J RodenburgJohn J P Kastelein
Jul 22, 2004·JAMA : the Journal of the American Medical Association·Albert WiegmanJohn J P Kastelein
Jan 7, 2005·The New England Journal of Medicine·Paul M RidkerUNKNOWN Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Inv

❮ Previous
Next ❯

Citations

Nov 23, 2006·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Anna WasilewskaEdyta Tenderenda
Sep 9, 2006·Current Opinion in Lipidology·Ian S Young, D Paul Nicholls
May 22, 2008·International Journal of Clinical Practice·D P NichollsI S Young
Dec 19, 2015·Critical Reviews in Clinical Laboratory Sciences·Menuka Pallebage-GamarallageJohn Mamo
Mar 10, 2010·Expert Opinion on Pharmacotherapy·D Meeike KustersBarbara A Hutten
Jun 1, 2008·Journal of Clinical Lipidology·Brian W McCrindle, Cedric Manlhiot
Oct 25, 2006·Journal of Thrombosis and Haemostasis : JTH·G Hoffmann
Mar 16, 2007·European Journal of Clinical Investigation·H M ChengM J Charng
Jun 12, 2008·Redox Report : Communications in Free Radical Research·Fatma Ferda VeritHakim Celik
May 15, 2007·Journal of the American College of Cardiology·Francesco MartinoFrancesco Violi
Dec 22, 2007·Arteriosclerosis, Thrombosis, and Vascular Biology·Mireia JunyentEmilio Ros
Feb 23, 2019·Journal of Veterinary Internal Medicine·Romy M HeilmannJörg M Steiner
Oct 22, 2019·Journal of Internal Medicine·I NarverudK B Holven
Jul 11, 2019·European Journal of Preventive Cardiology·Fabrizio MontecuccoAmirhossein Sahebkar
Apr 11, 2015·Angiology·Atilla IcliAbdullah Dogan
Jul 14, 2017·Journal of Lipid Research·Andrew C MartinGerald F Watts
Sep 17, 2008·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Yan ZhaoNagara Tamaki

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.